137 related articles for article (PubMed ID: 17614761)
1. Novel therapeutic targets in mantle cell lymphoma.
Martin P; Leonard JP
Expert Opin Ther Targets; 2007 Jul; 11(7):929-40. PubMed ID: 17614761
[TBL] [Abstract][Full Text] [Related]
2. Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon?
El Halabi L; Ghez D; Ribrag V
Expert Rev Hematol; 2016 Mar; 9(3):271-81. PubMed ID: 26689790
[TBL] [Abstract][Full Text] [Related]
3. The molecular pathogenesis of mantle cell lymphoma.
Vogt N; Dai B; Erdmann T; Berdel WE; Lenz G
Leuk Lymphoma; 2017 Jul; 58(7):1530-1537. PubMed ID: 27894215
[TBL] [Abstract][Full Text] [Related]
4. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.
Jares P; Colomer D; Campo E
Nat Rev Cancer; 2007 Oct; 7(10):750-62. PubMed ID: 17891190
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.
Lo RK; Kwong YL
Ann Hematol; 2014 Feb; 93(2):255-65. PubMed ID: 23949314
[TBL] [Abstract][Full Text] [Related]
6. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy.
Silkenstedt E; Arenas F; Colom-Sanmartí B; Xargay-Torrent S; Higashi M; Giró A; Rodriguez V; Fuentes P; Aulitzky WE; van der Kuip H; Beà S; Toribio ML; Campo E; López-Guerra M; Colomer D
J Exp Clin Cancer Res; 2019 Nov; 38(1):446. PubMed ID: 31676012
[TBL] [Abstract][Full Text] [Related]
7. Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.
Yang Q; Chen LS; Ha MJ; Do KA; Neelapu SS; Gandhi V
Clin Cancer Res; 2017 Jan; 23(1):181-192. PubMed ID: 27342398
[TBL] [Abstract][Full Text] [Related]
8. Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma.
Klener P
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500350
[TBL] [Abstract][Full Text] [Related]
9. Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment.
Papin A; Le Gouill S; Chiron D
Leuk Lymphoma; 2018 May; 59(5):1064-1072. PubMed ID: 28758825
[TBL] [Abstract][Full Text] [Related]
10. Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies.
Nastoupil LJ; Koff JL; Flowers CR
Oncology (Williston Park); 2013 Oct; 27 Suppl 2():8-12. PubMed ID: 25374999
[TBL] [Abstract][Full Text] [Related]
11. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9.
Georgakis GV; Li Y; Younes A
Br J Haematol; 2006 Oct; 135(1):68-71. PubMed ID: 16925576
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697
[TBL] [Abstract][Full Text] [Related]
13. Flipping the cyclin D1 switch in mantle cell lymphoma.
Hasanali Z; Sharma K; Epner E
Best Pract Res Clin Haematol; 2012 Jun; 25(2):143-52. PubMed ID: 22687450
[TBL] [Abstract][Full Text] [Related]
14. Mantle cell lymphoma in relapse: the role of emerging new drugs.
Diefenbach CS; O'Connor OA
Curr Opin Oncol; 2010 Sep; 22(5):419-23. PubMed ID: 20679769
[TBL] [Abstract][Full Text] [Related]
15. The antitumor effects of arsenic trioxide in mantle cell lymphoma via targeting Wnt/β‑catenin pathway and DNA methyltransferase-1.
Li XY; Li Y; Zhang L; Liu X; Feng L; Wang X
Oncol Rep; 2017 Nov; 38(5):3114-3120. PubMed ID: 28901456
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV.
de Vos S; Krug U; Hofmann WK; Pinkus GS; Swerdlow SH; Wachsman W; Grogan TM; Said JW; Koeffler HP
Diagn Mol Pathol; 2003 Mar; 12(1):35-43. PubMed ID: 12605034
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways.
Fernàndez V; Hartmann E; Ott G; Campo E; Rosenwald A
J Clin Oncol; 2005 Sep; 23(26):6364-9. PubMed ID: 16155021
[TBL] [Abstract][Full Text] [Related]
18. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells.
Prasad A; Park IW; Allen H; Zhang X; Reddy MV; Boominathan R; Reddy EP; Groopman JE
Oncogene; 2009 Mar; 28(12):1518-28. PubMed ID: 19198627
[TBL] [Abstract][Full Text] [Related]
19. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
[TBL] [Abstract][Full Text] [Related]
20. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
